Abstract
Renal cell carcinoma (RCC) represents five percent of adult epithelial cancers and clear cell RCC is the most frequent histological subtype. Improved understanding of the molecular pathways implicated in the pathogenesis of RCC has led to the development of specific targeted therapies to treat the disease. Five new medications have been shown to increase progression-free survival (PFS) in patients with metastatic clear cell RCC: bevacizumab, sorafenib, sunitinib, everolimus, and temsirolimus. Bevacizumab (+ interferon-alpha), sunitinib, and temsirolimus (in poor-risk groups) have proven to be effective as first-line palliative treatments. Sorafenib has demonstrated benefits in patients that have failed prior therapy, as has everolimus after failure of sorafenib and/or sunitinib. This paper provides a comprehensive review of the new targeted therapies currently available in clinical practice to treat patients with metastatic unresectable renal cell carcinoma. The relevant patents are discussed.
Keywords: Angiogenesis inhibitors, mTOR inhibitors, renal cell carcinoma, toxicity
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Volume: 4 Issue: 2
Author(s): Emmanuel Seront and Jean-Pascal Machiels
Affiliation:
Keywords: Angiogenesis inhibitors, mTOR inhibitors, renal cell carcinoma, toxicity
Abstract: Renal cell carcinoma (RCC) represents five percent of adult epithelial cancers and clear cell RCC is the most frequent histological subtype. Improved understanding of the molecular pathways implicated in the pathogenesis of RCC has led to the development of specific targeted therapies to treat the disease. Five new medications have been shown to increase progression-free survival (PFS) in patients with metastatic clear cell RCC: bevacizumab, sorafenib, sunitinib, everolimus, and temsirolimus. Bevacizumab (+ interferon-alpha), sunitinib, and temsirolimus (in poor-risk groups) have proven to be effective as first-line palliative treatments. Sorafenib has demonstrated benefits in patients that have failed prior therapy, as has everolimus after failure of sorafenib and/or sunitinib. This paper provides a comprehensive review of the new targeted therapies currently available in clinical practice to treat patients with metastatic unresectable renal cell carcinoma. The relevant patents are discussed.
Export Options
About this article
Cite this article as:
Seront Emmanuel and Machiels Jean-Pascal, Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452803
DOI https://dx.doi.org/10.2174/157489209788452803 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets MicroRNA-203: Tumor Suppression and Beyond
MicroRNA The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Anti-Cancer Agents in Medicinal Chemistry Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism Vinorelbine in Cancer Therapy
Current Drug Targets Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
Current Cancer Drug Targets Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Synthetic Peptides Derived from the C-Terminal Region of Lys49 Phospholipase A2 Homologues from Viperidae Snake Venoms: Biomimetic Activities and Potential Applications
Current Pharmaceutical Design